Taghizadeh, H.; Maj-Hes, A.; Prager, G.W.; Müllauer, L.; Mader, R.M.
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. Cancers 2022, 14, 1936.
https://doi.org/10.3390/cancers14081936
AMA Style
Taghizadeh H, Maj-Hes A, Prager GW, Müllauer L, Mader RM.
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. Cancers. 2022; 14(8):1936.
https://doi.org/10.3390/cancers14081936
Chicago/Turabian Style
Taghizadeh, Hossein, Agnieszka Maj-Hes, Gerald W. Prager, Leonhard Müllauer, and Robert M. Mader.
2022. "Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors" Cancers 14, no. 8: 1936.
https://doi.org/10.3390/cancers14081936
APA Style
Taghizadeh, H., Maj-Hes, A., Prager, G. W., Müllauer, L., & Mader, R. M.
(2022). Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. Cancers, 14(8), 1936.
https://doi.org/10.3390/cancers14081936